Abstract
Recent advances in the molecular characterization of Philadelphia chromosome-negative (Ph-) leukemias and related myeloid disorders have provided a clear rationale for investigating novel targeted therapies. Dasatinib is a tyrosine kinase inhibitor with activity against BCR-ABL, platelet-derived growth factor receptors (PDGFRs), c- KIT, fibroblast growth factor receptors (FGFRs), SRC family kinases (SFKs), and EPHA receptors, all of which have been implicated in the pathogenesis of Ph- leukemias and myeloid disorders. This review presents emerging data on the preclinical and clinical activity of dasatinib in these diseases, which suggest that larger clinical studies are warranted.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 617-623 |
| Number of pages | 7 |
| Journal | Leukemia Research |
| Volume | 33 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2009 |
Keywords
- Dasatinib
- Leukemia
- Myelodysplastic syndrome
- Myeloid
- Myeloproliferative neoplasm
- Philadelphia-negative
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Preclinical and clinical experience with dasatinib in philadelphia chromosome-negative leukemias and myeloid disorders'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS